Omicron News and Research

RSS

Prediction of waning COVID-19 vaccine efficacy against Omicron variant

Researchers performed a meta-analysis of the results of four previous studies estimating fold-drop in neutralization titer against Omicron to present a combined estimate of the same.

17 Dec 2021

Analysis of the alteration of neutralizing titers with Omicron pseudovirus

A new study measured antibody levels from blood samples of vaccinated individuals and individuals who recovered from COVID-19 illness.

17 Dec 2021

Comparison of RBD/ACE2 receptor complex in wild type SARS-CoV-2 and Omicron variant

New research details the molecular landscape of Omicron’s RBD and how it differs from the original SARS-CoV-2 strain.

17 Dec 2021

25 million people in the UK have had COVID-19 top up jab

More than 25 million people in the UK have had a COVID-19 top up jab, as the vaccination programme is turbocharged to get all eligible adults boosted as soon as possible.

16 Dec 2021

G7 health ministers issue statement on the global threat of Omicron variant

G7 health ministers today held their final meeting of the UK's G7 Presidency, focusing particularly on the very worrying developments on Omicron.

16 Dec 2021

Antibody-like proteins derived from sharks may be used to combat future SARS outbreaks

Small, unique antibody-like proteins known as VNARs - derived from the immune systems of sharks - can prevent the virus that causes COVID-19, its variants, and related coronaviruses from infecting human cells, according to a new study published Dec. 16.

16 Dec 2021

KHN’s ‘What the Health?’: Oh, oh, omicron

This week, the U.S. passed the milestone of 800,000 dead from covid-19, as hospitals are starting to fill following the Thanksgiving holiday and the ominous omicron variant starts to spread rapidly.

16 Dec 2021

New study demonstrates SARS-CoV-2 Omicron antibody escape

A new study examined the neutralization of virus variants using three sets of antibodies: serum from individuals vaccinated or infected with earlier variants of the virus; concentrated human antibodies from plasma donors; and approved monoclonal antibodies.

16 Dec 2021

Moderna booster vaccination overcomes SARS-CoV-2 Omicron variant antibody escape

A new study reports the results of a study focused on immune evasion characteristics, specifically the ability to escape neutralization by antibodies to the earlier SARS-CoV-2 variants or to the spike antigen used in COVID-19 vaccines.

16 Dec 2021

Therapeutic antibodies deemed ineffective against Omicron variant of SARS-CoV-2

A new study found that the Omicron S protein evades antibodies with a 44-fold higher efficiency than the Delta variant's spike, rendering therapeutic antibodies ineffective and likely negatively impacting antibody protection induced by infection or double vaccination.

16 Dec 2021

Capability of BNT162b2 vaccine given in 2 or 3 doses to neutralize SARS-CoV-2 Omicron

The team observed that three doses of the BNT162b2 (Pfizer-BioNTech) mRNA vaccine are required to mount an effective antibody response against the Omicron variant.

16 Dec 2021

T cell responses remain broadly robust against Omicron variant of SARS-CoV-2

A new study highlights the significance of robust T cell responses in preventing severe omicron infections.

16 Dec 2021

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

A new study has used this assay to evaluate sera, obtained from 239 individuals vaccinated via any of the above-stated vaccines against SARS-CoV-2’s original strain, the Delta, and Omicron SARS-CoV-2 pseudoviruses.

16 Dec 2021

Exploring the plasma neutralization properties of the Omicron variant of SARS-CoV-2

A new study determines the ability of individuals with varying exposure to SARS-CoV-2 infection and vaccination, to neutralize SARS- CoV-2 pseudotypes.

16 Dec 2021

Study suggests Omicron can be neutralized by BNT162b2 recipient sera optimally after three vaccine doses

Researchers from Westmead Hospital have been investigating the effect of a third dose on neutralizing antibody titres in already vaccinated individuals.

16 Dec 2021

Omicron is more transmissible but may have milder symptoms for many people, expert says

If the first reports coming out of South Africa are correct, Omicron might be more transmissible than the current dominant Covid-19 strain, Delta, but cause less severe symptoms for many people. A leading expert says that, if the new strain does turn out to be milder for some people, that creates a new set of problems.

16 Dec 2021

Two doses of Moderna COVID-19 vaccine highly effective against all SARS-CoV-2 variants

Kaiser Permanente research published on December 15, 2021 in The British Medical Journal showed 2 doses of Moderna COVID-19 vaccine were highly effective against all SARS-CoV-2 variants; however, vaccine effectiveness against the delta variant moderately declined with increasing time after vaccination.

15 Dec 2021

Omicron News and Research

Prediction of waning COVID-19 vaccine efficacy against Omicron variant

Analysis of the alteration of neutralizing titers with Omicron pseudovirus

Comparison of RBD/ACE2 receptor complex in wild type SARS-CoV-2 and Omicron variant

25 million people in the UK have had COVID-19 top up jab

G7 health ministers issue statement on the global threat of Omicron variant

Antibody-like proteins derived from sharks may be used to combat future SARS outbreaks

KHN’s ‘What the Health?’: Oh, oh, omicron

New study demonstrates SARS-CoV-2 Omicron antibody escape

Moderna booster vaccination overcomes SARS-CoV-2 Omicron variant antibody escape

Therapeutic antibodies deemed ineffective against Omicron variant of SARS-CoV-2

Capability of BNT162b2 vaccine given in 2 or 3 doses to neutralize SARS-CoV-2 Omicron

T cell responses remain broadly robust against Omicron variant of SARS-CoV-2

Neutralization potency of COVID-19 vaccine boosters against SARS-CoV-2 variant pseudoviruses

Exploring the plasma neutralization properties of the Omicron variant of SARS-CoV-2

Study suggests Omicron can be neutralized by BNT162b2 recipient sera optimally after three vaccine doses

Omicron is more transmissible but may have milder symptoms for many people, expert says

Two doses of Moderna COVID-19 vaccine highly effective against all SARS-CoV-2 variants

Evaluation of SARS-CoV-2 neutralizing antibodies in mothers and infants

Evaluation of SARS-CoV-2 Omicron's immune evasion potential

SARS-CoV-2 VOCs dependent on IFITM2 for efficient infection establishment

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News